ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

Company to share preclinical data from lead program in autoimmune disease at American College of Rheumatology (ACR) Convergence 2022

Excerpt from the Press Release:

BOSTON–(BUSINESS WIRE)–ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it will share preclinical data from its lead program, a LINE-1 reverse transcriptase inhibitor, in a poster presentation at American College of Rheumatology (ACR) Convergence 2022, taking place November 10 – 14, 2022, in Philadelphia.

LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome. eRTs convert RNA into DNA in the cytosol, triggering a viral mimicry response via nucleic acid-sensors, such as cGAS, resulting in activation of Type 1 interferon and NFκB pathways. Since excess activation of these pathways can lead to autoimmune disease, eRT inhibitors have great potential to improve pathological outcomes.

Through rational structure-based drug design, ROME identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase. The data show that ROME’s compound inhibited a Type 1 interferon response in multiple in vivo and in vitro models of autoimmune disease.

Click the button below to read the entire Press Release:

Continue Reading The Press Release